Beam Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 34 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 49.25.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Beam Therapeutics Inc is 7.79, ranking 66 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 114.11M, representing a year-over-year increase of 279.52%, while its net profit experienced a year-over-year increase of 370.38%.
Key Metrics
The current valuation score of Beam Therapeutics Inc is 6.32, ranking 294 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -27.44, which is -88.51% below the recent high of -3.15 and -33.44% above the recent low of -36.61.
The current earnings forecast score of Beam Therapeutics Inc is 8.74, ranking 67 out of 391 in the Biotechnology & Medical Research industry. The average price target is 42.00, with a high of 80.00 and a low of 21.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Beam Therapeutics Inc is 6.53, ranking 205 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 26.78 and the support level at 19.79, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Beam Therapeutics Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 114.47%, representing a quarter-over-quarter decrease of 1.20%. The largest institutional shareholder is Catherine Wood, holding a total of 12.47M shares, representing 12.24% of shares outstanding, with 45.14% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Beam Therapeutics Inc is 4.52, ranking 81 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 2.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Beam Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
